⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18320321 | 0.97 | — | — | |
| SCHEMBL24084053 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL24660169 | 0.77 | — | — | |
| SCHEMBL11185123 | 0.75 | — | — | |
| SCHEMBL23265527 | 0.73 | — | — | |
| SCHEMBL1857320 | 0.73 | — | — | |
| SCHEMBL10354603 | 0.73 | — | — | |
| SCHEMBL23018203 | 0.73 | ALDH1A1 (0.43) | — | |
| SCHEMBL2074943 | 0.73 | — | — | |
| SCHEMBL13531609 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | claimed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | claimed |
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117105933-A | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-112969505-B | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070244111-A1 | Pyrazolopyrimidines | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244111-A1 | Pyrazolopyrimidines | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
| EP-1732893-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | Pfizer Japan, Inc. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |